RxDoctor Payments Data

Karen Oxford, MD

Ophthalmology · San Francisco, CANPI 1396746749

Payments from drug & device makers

$4,703in general payments, 2019–2025

Across 190 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$517
  • Oyster Point Pharma, Inc.$475
  • Alcon$421
  • Biotissue Holdings Inc.$339
  • Bausch & Lomb Americas Inc.$335
  • plus $935 from 13 others

What the payments were for

  • Food & beverage$4,66799%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,703 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$314,178
Medicare patients
1,168
Services billed
2,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast73$70,256
MieboPerfluorohexyloctane/Pf82$61,519
LumiganBimatoprost67$21,752
TyrvayaVarenicline Tartrate25$18,555
RestasisCyclosporine15$17,234
Difluprednate91$8,062
Travoprost28$6,906
Alphagan PBrimonidine Tartrate14$5,083
TafluprostTafluprost/Pf31$4,768
Timolol MaleateTimolol Maleate/Pf18$4,418
Timolol Maleate40$3,538
Loteprednol Etabonate17$2,957
MoxifloxacinMoxifloxacin Hcl117$1,759
Prednisolone Acetate33$1,455
Ketorolac Tromethamine112$1,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$335$131,775155 claims
AbbVieLumigan, Restasis, Alphagan P$1,682$44,06996 claims
Oyster Point Pharma, Inc.Tyrvaya$475$18,55525 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$184$2,95717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →